Optimizing Treatment of Lung Cancer Patients with Comorbidities
Technical Report,30 Sep 2017,29 Sep 2018
Icahn School of Medicine at Mount Sinai New York United States
Pagination or Media Count:
The overall goal of this project is to improve the management of military personnel and Veterans with localized lung cancer and comorbidities. The Specific Aims are to 1 Enhance and validate the Lung Cancer Policy Model to simulate the management and subsequent outcomes of military personnel and Veterans with early stage lung cancer and specific comorbidities 2 Determine the optimal management and indications for lobectomy, elective limited resection, stereotactic body radiotherapy, and other treatments for military personnel and Veterans with stage I NSCLC and chronic lung or heart disease as well as by overall burden of comorbidities and 3 Determine the optimal indications for adjuvant chemotherapy in military personnel and Veterans with stage II and IIIA NSCLC and chronic lung, heart, or renal disease and by overall burden of comorbidities. We have completed the majority of analyses to inform the parameter estimates for our simulation models that will ultimately provide guidance regarding optimal treatment of lung cancer patients with major comorbid illnesses. Most contributing analyses involved national VA health data we identified a cohort of 20,000 NSCLC patients and collected data on comorbidities, cancer treatments and outcomes to generate estimates of treatment complications, overall survival and quality of life. These results are currently being incorporated into the well-validated Lung Cancer Policy Model to generate specific treatment recommendations.
- Medicine and Medical Research